Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in the virtual BMO Biopharma Spotlight Series on August 12, 2021. Terrie Curran, the company's President and CEO, will be part of the "Innovation in GI" panel discussion at 10:50 a.m. ET. Additionally, Phathom management will engage in one-on-one meetings during the event. An on-demand webcast will be accessible on their website for 30 days post-event. Phathom specializes in developing treatments for gastrointestinal diseases and has in-licensed vonoprazan, a late-stage P-CAB treatment for acid-related disorders.

FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Phathom’s President and Chief Executive Officer, will participate in the “Innovation in GI” panel discussion at the BMO Biopharma Spotlight Series virtual conference on Thursday, August 12, 2021 at 10:50 a.m. ET.  

Company management will also participate in one-on-one meetings during the virtual conference.

The on-demand webcast can be accessed under the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 30 days following the event.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.

CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Joe Hand
1-877-742-8466
ir@phathompharma.com

FAQ

What is Phathom Pharmaceuticals' participation in the BMO Biopharma Spotlight Series?

Phathom Pharmaceuticals will participate in the BMO Biopharma Spotlight Series on August 12, 2021, where CEO Terrie Curran will join the "Innovation in GI" panel.

When will Terrie Curran speak during the BMO Biopharma Spotlight Series?

Terrie Curran will speak at 10:50 a.m. ET on August 12, 2021.

How can I access the Phathom Pharmaceuticals webcast?

The on-demand webcast can be accessed on the Phathom Pharmaceuticals website in the News & Events section.

What is vonoprazan and its significance for Phathom Pharmaceuticals?

Vonoprazan is a novel potassium competitive acid blocker (P-CAB) that Phathom has in-licensed for late-stage development for treating acid-related disorders.

What types of diseases does Phathom Pharmaceuticals focus on?

Phathom Pharmaceuticals focuses on developing treatments for gastrointestinal diseases and disorders.